Covalon Technologies Ltd. Selected as a 2025 OTCQX Best 50 Company
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has been named one of the 2025 OTCQX Best 50 companies, ranking #4 overall and emerging as the top Medical Device company. The recognition is based on total return and growth in average daily dollar volume throughout 2024.
The company achieved a remarkable 207% total return in 2024, significantly outperforming the Best 50 median of 74%. The OTCQX Best 50 companies collectively traded over $5.8 billion in dollar volume during 2024, with representatives from the United States, Canada, the United Kingdom, Australia, and Turkey.
CEO Brent Ashton highlighted that this achievement demonstrates Covalon's growing international investor following and recognition of its long-term potential. The company reports accelerated interest from both sophisticated microcap communities and institutional healthcare investors.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) è stata nominata una delle 50 migliori aziende OTCQX del 2025, classificandosi al #4 posto in generale e risultando la migliore azienda nel settore dei dispositivi medici. Il riconoscimento si basa sul ritorno totale e sulla crescita del volume medio giornaliero in dollari per tutto il 2024.
L'azienda ha raggiunto un notevole 207% di ritorno totale nel 2024, superando significativamente la mediana del 74% delle Migliori 50. Le aziende del OTCQX Best 50 hanno complessivamente negoziato oltre 5,8 miliardi di dollari di volume durante il 2024, con rappresentanti provenienti dagli Stati Uniti, Canada, Regno Unito, Australia e Turchia.
Il CEO Brent Ashton ha sottolineato che questo risultato dimostra l'aumento dell'interesse internazionale verso Covalon e il riconoscimento del suo potenziale a lungo termine. L'azienda riporta un interesse crescente sia da parte di comunità di microcap sofisticate che di investitori istituzionali nel settore sanitario.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) ha sido nombrada una de las 50 mejores empresas OTCQX de 2025, ocupando el puesto #4 en general y emergiendo como la mejor empresa de dispositivos médicos. El reconocimiento se basa en el retorno total y el crecimiento del volumen diario promedio en dólares a lo largo de 2024.
La compañía logró un notable 207% de retorno total en 2024, superando significativamente la mediana del 74% de las Mejores 50. Las empresas del OTCQX Best 50 negociaron colectivamente más de 5,8 mil millones de dólares en volumen durante 2024, con representantes de Estados Unidos, Canadá, Reino Unido, Australia y Turquía.
El CEO Brent Ashton destacó que este logro demuestra el creciente seguimiento de inversores internacionales hacia Covalon y el reconocimiento de su potencial a largo plazo. La empresa informa un interés acelerado tanto de las sofisticadas comunidades microcap como de los inversores institucionales en el sector de la salud.
코발론 테크놀로지스 (TSXV: COV; OTCQX: CVALF)는 2025 OTCQX 베스트 50 기업 중 하나로 선정되어 전체 4위를 기록하며 의료 기기 기업 중 1위에 올랐습니다. 이 인식은 2024년 동안의 총 수익률 및 평균 일일 달러 거래량의 성장에 기반하고 있습니다.
회사는 2024년 동안 207%의 총 수익률을 달성하여, 베스트 50의 중간 수익률인 74%를 크게 초과했습니다. OTCQX 베스트 50 기업들은 2024년 동안 총 58억 달러 이상 거래되었으며, 미국, 캐나다, 영국, 호주 및 터키의 대표들이 포함되었습니다.
CEO 브렌트 애쉬턴은 이 성과가 코발론에 대한 국제 투자자의 관심이 커지고 있으며 장기적인 잠재력을 인정받고 있음을 보여준다고 강조했습니다. 회사는 정교한 마이크로캡 커뮤니티와 기관 의료 투자자들로부터 관심이 증가하고 있다고 보고하고 있습니다.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) a été nommée l'une des 50 meilleures entreprises OTCQX de 2025, se classant au 4e rang général et se distinguant comme la meilleure entreprise de dispositifs médicaux. Ce prix est basé sur le rendement total et la croissance du volume quotidien moyen en dollars tout au long de l'année 2024.
L'entreprise a réalisé un rendement total remarquable de 207% en 2024, dépassant largement la médiane de 74% des 50 meilleures. Les entreprises du classement OTCQX Best 50 ont collectivement échangé plus de 5,8 milliards de dollars de volume durant l'année 2024, avec des représentants des États-Unis, du Canada, du Royaume-Uni, d'Australie et de Turquie.
Le PDG Brent Ashton a souligné que cette réalisation démontre l'intérêt croissant des investisseurs internationaux pour Covalon et la reconnaissance de son potentiel à long terme. L'entreprise signale un intérêt accru tant de la part de communautés de micro-cap sophistiquées que d'investisseurs institutionnels dans le domaine de la santé.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) wurde als eines der 50 besten Unternehmen OTCQX 2025 benannt und belegt insgesamt den 4. Platz, dabei ist es das beste Unternehmen im Bereich der Medizintechnik. Die Anerkennung basiert auf der Gesamtrendite und dem Wachstum des durchschnittlichen täglichen Dollarumsatzes im Jahr 2024.
Das Unternehmen erreichte eine bemerkenswerte 207% Gesamtrendite im Jahr 2024, was die Medianrendite der Besten 50 von 74% erheblich übertraf. Die OTCQX Best 50 Unternehmen handelten während des Jahres 2024 insgesamt über 5,8 Milliarden Dollar, mit Vertretern aus den Vereinigten Staaten, Kanada, dem Vereinigten Königreich, Australien und der Türkei.
CEO Brent Ashton hob hervor, dass dieser Erfolg das wachsende internationale Interesse an Covalon und die Anerkennung seines langfristigen Potenzials demonstriert. Das Unternehmen berichtet von steigenden Interessen sowohl seitens anspruchsvoller Mikrocap-Gemeinschaften als auch von institutionellen Gesundheitsinvestoren.
- Ranked #4 in 2025 OTCQX Best 50 companies
- Achieved 207% total return in 2024
- Named top Medical Device company in the OTCQX Best 50
- Growing international investor following
- None.
Company ranked as #4 overall and the top Medical Device company
The 2025 OTCQX Best 50 is comprised of companies that collectively traded more than
“Being named to the OTCQX Best 50 is a significant achievement and clearly demonstrates that Covalon is developing an international following among investors who recognize the long-term potential for Covalon,” said Brent Ashton, CEO of Covalon Technologies. “We are immensely grateful to our investors for their support, which has been instrumental in our success.”
“As the Company builds momentum with new investors, we are continuing to work with our strong investor base in
For more details on the 2025 OTCQX® Best 50, visit:
https://www.globenewswire.com/news-release/2025/01/15/3009889/0/en/OTC-Markets-Group-Announces-the-2025-OTCQX-Best-50.html
To learn more about Covalon, please visit our website at www.covalon.com or contact us at investors@covalon.com.
About Covalon
Covalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203969534/en/
To learn more about Covalon, please visit our website at www.covalon.com or contact us at investors@covalon.com.
Source: Covalon Technologies Ltd.
FAQ
What was Covalon Technologies (CVALF) ranking in the 2025 OTCQX Best 50?
What was Covalon Technologies (CVALF) total return in 2024?
How much trading volume did the 2025 OTCQX Best 50 companies generate in 2024?
Which countries were represented in the 2025 OTCQX Best 50 list?
